Announcements

FNIH Biomarkers Consortium Project Will Establish New Methods for Detecting Disease in Acute Myeloid Leukemia

The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) has launched a project to validate new methods of detecting and quantifying the small amount of cancer cells remaining in the body following anti-cancer therapy, or measurable residual disease (MRD), in patients with acute myeloid leukemia (AML).

FNIH Biomarkers Consortium Confirms Blood Tests Provide a Key Research Tool for Measuring Amyloid Accumulation in Alzheimer’s Disease

North Bethesda, MD, July 26, 2021—The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) has evaluated several blood tests that can detect one of the known characteristics of Alzheimer’s disease (AD).

Three Questions with Sarcopenia 2 Principal Investigators Dr. Shalender Bhasin and Dr. Peggy Cawthon

 September 21, 2020 — The FNIH Biomarkers Consortium Sarcopenia 2 project, Sarcopenia as a Valid Biomarker for Identifying Individuals at Risk of Disability, recently achieved the key milestone of publishing seven articles in The Journal of the American Geriatrics Society and The Journals of Gerontology